ClinicalTrials.gg
CompletedNCT03746535Updated Oct 16, 2026Results posted

Cardiovascular Disease Risk in Women With Endometriosis

An Early Phase 1 interventional study of Elagolix in Endometriosis, sponsored by Yale University. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Yale University · Early Phase 1, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing elagolix in Endometriosis — 2 open to participants now, 4 under way, 2 of them phase 3. elagolix · Endometriosis.

Enrollment
20th of 22
21 · median 165
Started
2022
with 3 others
Phase 1
3 of 22
none open now
Registered
13th of 22
by date
Lead sponsor
3 of 22
Yale University

Among the 22 studies testing elagolix in Endometriosis, this one is the 20th largest by enrollment, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 13th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

2 of the 22 studies testing elagolix in Endometriosis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elagolix

elagolix: first FDA approval 2018 (ORILISSA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing elagolix in Endometriosis, or all of them as a file.
02

Study summary

To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.

Read the detailed description

Our scientific premise is that in women with endometriosis, elevated cardiovascular disease risk is the result of endothelial dysfunction and chronic systemic inflammation through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • endometriosis, elagolix, ntradermal microdialysis, GnRH antagonist, flow mediated vasodilation
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Young women between the ages of 18 and 45 years (Controls);
  • Young women between the ages of 18 and 45 years with endometriosis.

Exclusion criteria

Exclusion Criteria:

  • Subjects who smoke
  • Subjects who have diabetes,
  • Subjects with sleep apnea or BP>140/90 will be excluded.
  • Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Active comparator
    patients without endometriosis

    Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis

    Drug: Elagolix

  • Experimental
    patients with endometriosis

    Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.

    Drug: Elagolix

Interventions

  • Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.

06

What researchers measure

Primary outcomes

  1. Flow Mediated Vasodilation

    Blood flow velocity measured using the Sonoscope S2 ultrasound imaging system. Percent change is measured pre and post cuff inflation at baseline and during intervention

    Time frame: Baseline and during intervention (1 month)

  2. Microdialysis Perfusions of Acetylcholine ED50

    Skin blood responses to perfusion of acetylcholine at baseline and during intervention

    Time frame: Baseline and during intervention (1 month)

  3. Microdialysis Perfusions of Acetylcholine Hill Slope

    hill slope of skin blood flow dose perfusions of acetylcholine into skin

    Time frame: baseline and during intervention (1 month)

  4. Microdialysis Perfusions of Estradiol ED50

    Skin blood responses to perfusion of estradiol at baseline and during intervention

    Time frame: Baseline and during intervention (1 month)

  5. Microdialysis Perfusions of Estradiol- Hill Slope

    hill slope of skin blood flow dose perfusions of estradiol into skin

    Time frame: Baseline and during intervention (1 month)

Secondary outcomes

  1. Plasma Estrogen Concentration

    blood draw, this is done on baseline and during intervention

    Time frame: Baseline and during intervention (1 month)

  2. Serum Concentration Progesterone

    Serum concentration progesterone at baseline and during intervention

    Time frame: Baseline and During intervention (1 month)

  3. Serum Sex Hormone Binding Globulin Concentration

    Serum concentration of sex hormone binding globulin concentration taken a baseline and during intervention

    Time frame: Baseline and During intervention (1 month)

07

Results

Posted Oct 16, 2026
Limitations and caveats
This was a difficult study to recruit subjects into because many women with endometriosis are already taking hormonal treatments so had to be excluded. Thus, completing the study took longer than expected.

Participant flow

Subjects were recruited using posters in the greater New Haven area, through advertisements on the Yale School of Medicine online listings for Clinical Research Studies for Volunteers, by contacting women who had consented to being contacted for future research through the Yale Center for Clinical Investigation for Clinical Research Studies and through Yale New Haven Hospital's MyChart system, through our laboratory and departmental websites and through social media.

Participant flow — Overall Study
MilestonePatients Without EndometriosisPatients With Endometriosis
Started138
Completed128
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryFlow Mediated Vasodilation

Blood flow velocity measured using the Sonoscope S2 ultrasound imaging system. Percent change is measured pre and post cuff inflation at baseline and during intervention

Time frame:
Baseline and during intervention (1 month)
Reported as:
Mean · percent change
Flow Mediated Vasodilation
percent changePatients Without EndometriosisPatients With Endometriosis
Baseline12.5 ± 4.259.49 ± 4.17
During intervention9.57 ± 4.577.62 ± 4.19
Statistical analysis
  • Patients Without Endometriosis vs Patients With Endometriosis · ANOVA · p = 0.05 · Mean difference (final values): 4
PrimaryMicrodialysis Perfusions of Acetylcholine ED50

Skin blood responses to perfusion of acetylcholine at baseline and during intervention

Time frame:
Baseline and during intervention (1 month)
Reported as:
Mean · log M
Microdialysis Perfusions of Acetylcholine ED50
log MPatients Without EndometriosisPatients With Endometriosis
Baseline-3.38 ± 1.08-2.83 ± 1.20
During intervention-2.49 ± 0.89-3.49 ± 1.50
PrimaryMicrodialysis Perfusions of Acetylcholine Hill Slope

hill slope of skin blood flow dose perfusions of acetylcholine into skin

Time frame:
baseline and during intervention (1 month)
Reported as:
Mean · Moles/%variability
Microdialysis Perfusions of Acetylcholine Hill Slope
Moles/%variabilityPatients Without EndometriosisPatients With Endometriosis
Baseline1.38 ± 2.202.35 ± 1.80
During intervention2.31 ± 1.852.78 ± 1.43
SecondaryPlasma Estrogen Concentration

blood draw, this is done on baseline and during intervention

Time frame:
Baseline and during intervention (1 month)
Reported as:
Mean · pg/ml
Plasma Estrogen Concentration
pg/mlWomen Without EndometriosisWomen With Endometriosis
Baseline24.4 ± 15.913.7 ± 4.4
During intervention24.4 ± 15.913.7 ± 4.4
SecondarySerum Concentration Progesterone

Serum concentration progesterone at baseline and during intervention

Time frame:
Baseline and During intervention (1 month)
Reported as:
Mean · ng/ml
Serum Concentration Progesterone
ng/mlWomen Without EndometriosisWomen With Endometriosis
Baseline0.9 ± 0.41.3 ± 0.6
During intervention0.9 ± 0.30.9 ± 0.7
SecondarySerum Sex Hormone Binding Globulin Concentration

Serum concentration of sex hormone binding globulin concentration taken a baseline and during intervention

Time frame:
Baseline and During intervention (1 month)
Reported as:
Mean · nmol/L
Serum Sex Hormone Binding Globulin Concentration
nmol/LWomen Without EndometriosisWomen With Endometriosis
Baseline197 ± 43144 ± 60
During intervention198 ± 4237 ± 55
PrimaryMicrodialysis Perfusions of Estradiol ED50

Skin blood responses to perfusion of estradiol at baseline and during intervention

Time frame:
Baseline and during intervention (1 month)
Reported as:
Mean · nanoMolar
Microdialysis Perfusions of Estradiol ED50
nanoMolarPatients Without EndometriosisPatients With Endometriosis
Baseline1.88 ± 0.081.95 ± 0.24
During interventions1.80 ± 0.132.90 ± 0.27
PrimaryMicrodialysis Perfusions of Estradiol- Hill Slope

hill slope of skin blood flow dose perfusions of estradiol into skin

Time frame:
Baseline and during intervention (1 month)
Reported as:
Mean · nanoMolar/L
Microdialysis Perfusions of Estradiol- Hill Slope
nanoMolar/LPatients With EndometriosisPatients Without Endometriosis
Baseline40.49 ± 5.833.29 ± 4.83
During intervention7.97 ± 5.836.88 ± 4.55

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Without Endometriosis0/13 (0%)0/13 (0%)0/13 (0%)
Patients With Endometriosis0/8 (0%)0/8 (0%)0/8 (0%)

Baseline characteristics

Baseline characteristics provided for all participants that completed.

Age, Categorical
Age, Categorical(Participants)Patients Without EndometriosisPatients With EndometriosisTotal
<=18 years000
Between 18 and 65 years12820
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Patients Without EndometriosisPatients With EndometriosisTotal
Female12820
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients Without EndometriosisPatients With EndometriosisTotal
Hispanic or Latino101
Not Hispanic or Latino11718
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients Without EndometriosisPatients With EndometriosisTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American213
White7512
More than one race202
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Patients Without EndometriosisPatients With EndometriosisTotal
United States12820
08

Study locations

1 site
  • Yale School of Medicine
    New Haven, Connecticut 06519, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2025, 34 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 24 phase 1 interventional studies under Endometriosis, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 26. This study's 34 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2025 → May 2025 and completion Dec 2026 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2018
First posted
Nov 19, 2018
StartActual
Jul 1, 2022
Primary completionActual
May 27, 2025was Dec 2025
CompletionActual
May 27, 2025was Dec 2026
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Results
Results posted
posted Oct 16, 2026
Primary completion
Dec 1, 2025→May 27, 2025 (actual)
Oct 16, 2026
Study completion
Dec 31, 2026→May 27, 2025 (actual)
Oct 16, 2026
Enrollment
40 (estimated)→21 (actual)
Oct 16, 2026
Primary outcomes
2 edited, 3 added
What changed in the outcomes
  • EditedFlow Mediated Vasodilation Microvascular skin blood flow analysisTime frame: 2 minutes → Baseline and during intervention (1 month)
  • EditedMicrodialysis perfusionsPerfusions of Acetylcholine ED50Time frame: 15 minutes → Baseline and during intervention (1 month)
  • AddedMicrodialysis Perfusions of Acetylcholine Hill SlopeTime frame: baseline and during intervention (1 month)
  • AddedMicrodialysis Perfusions of Estradiol ED50Time frame: Baseline and during intervention (1 month)
  • AddedMicrodialysis Perfusions of Estradiol- Hill SlopeTime frame: Baseline and during intervention (1 month)
Oct 16, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • AddedPlasma Estrogen ConcentrationTime frame: Baseline and during intervention (1 month)
  • AddedSerum Concentration ProgesteroneTime frame: Baseline and During intervention (1 month)
  • AddedSerum Sex Hormone Binding Globulin ConcentrationTime frame: Baseline and During intervention (1 month)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    Results posted
    Primary completion Dec 1, 2025→May 27, 2025 (now actual)
    Study completion Dec 31, 2026→May 27, 2025 (now actual)
    Enrollment 40 (estimated)→21 (actual)
    Primary outcomes 2 edited, 3 added
    What changed in the outcomes
    • EditedFlow Mediated Vasodilation Microvascular skin blood flow analysisTime frame: 2 minutes → Baseline and during intervention (1 month)
    • EditedMicrodialysis perfusionsPerfusions of Acetylcholine ED50Time frame: 15 minutes → Baseline and during intervention (1 month)
    • AddedMicrodialysis Perfusions of Acetylcholine Hill SlopeTime frame: baseline and during intervention (1 month)
    • AddedMicrodialysis Perfusions of Estradiol ED50Time frame: Baseline and during intervention (1 month)
    • AddedMicrodialysis Perfusions of Estradiol- Hill SlopeTime frame: Baseline and during intervention (1 month)
    Secondary outcomes 3 added
    What changed in the outcomes
    • AddedPlasma Estrogen ConcentrationTime frame: Baseline and during intervention (1 month)
    • AddedSerum Concentration ProgesteroneTime frame: Baseline and During intervention (1 month)
    • AddedSerum Sex Hormone Binding Globulin ConcentrationTime frame: Baseline and During intervention (1 month)
    + 6 other changes: verification date, conditions, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03746535
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Nov 19, 2018
Start date
Jul 1, 2022
Primary completion
May 27, 2025
Completion
May 27, 2025
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Nina Stachenfeld, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elagolix

Start the discussion